Cargando…

Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER

CONTEXT: Effectiveness and safety data on GH replacement therapy (GHRT) in older adults with adult GH deficiency (AGHD) are limited. OBJECTIVE: To compare GHRT safety and clinical outcomes in older (≥60 years and, for some outcomes, ≥75 years) and middle-aged (35–<60 years) patients with AGHD. DE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biller, Beverly M K, Höybye, Charlotte, Ferran, Jean-Marc, Kelepouris, Nicky, Nedjatian, Navid, Olsen, Anne Helene, Weber, Matthias M, Gordon, Murray B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184433/ https://www.ncbi.nlm.nih.gov/pubmed/37197408 http://dx.doi.org/10.1210/jendso/bvad054

Ejemplares similares

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program
por: Biller, Beverly M. K., et al.
Publicado: (2021)

Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet(®) IOS and Answer Program
por: Backeljauw, Philippe, et al.
Publicado: (2023)

Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER
por: Sävendahl, Lars, et al.
Publicado: (2021)

Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet(®) IOS and ANSWER Program
por: Sävendahl, Lars, et al.
Publicado: (2019)

CORRIGENDUM for “Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program”
Publicado: (2020)

Effectiveness and Safety of Early Growth Hormone Treatment in Children Born Small for Gestational Age: Long-Term Data From NordiNet® International Outcome Study (IOS) and ANSWER Program
por: Juul, Anders, et al.
Publicado: (2021)

Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study
por: Angulo, Moris, et al.
Publicado: (2020)

Abstract 2: Effectiveness and safety of early growth hormone treatment in children born small for gestational age: Long-term data from NordiNet® International Outcome Study (IOS) and ANSWER program
por: Ranjan, K M, et al.
Publicado: (2022)

Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
por: Höybye, Charlotte, et al.
Publicado: (2022)

LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS
por: Ross, Judith L, et al.
Publicado: (2022)

Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study
por: Blankenstein, Oliver, et al.
Publicado: (2017)

The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)
por: Höybye, Charlotte, et al.
Publicado: (2013)

Noonan syndrome and Turner syndrome patients respond similarly to 4 years’ growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program
por: Lee, Peter A., et al.
Publicado: (2015)

Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study
por: Polak, Michel, et al.
Publicado: (2017)

SAT-282 Outcomes in Children Treated with Growth Hormone for Prader-Willi Syndrome: Data from the Answer® Program and Nordinet® International Outcome Study (IOS)
por: Angulo, Moris, et al.
Publicado: (2019)

Metabolomics: a tool for the diagnosis of GH deficiency and for monitoring GH replacement?
por: Höybye, Charlotte, et al.
Publicado: (2014)

Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use
por: Hokken-Koelega, Anita, et al.
Publicado: (2011)

SAT-444 Pituitary Function and the Response to GH Replacement Therapy in Patients with Histiocytosis: Analysis of the Pfizer International Metabolic Database (KIMS)
por: Touraine, Philippe, et al.
Publicado: (2019)

Twenty Years of GH Treatment in Adults with Prader-Willi Syndrome
por: Sjöström, Anna, et al.
Publicado: (2021)

Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC)
por: Vyberg, Mogens, et al.
Publicado: (2015)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Is GH Replacement for Adult GH Deficiency Safe?
por: Melmed, Shlomo
Publicado: (2022)

Encoding Reversing Petri Nets in Answer Set Programming
por: Dimopoulos, Yannis, et al.
Publicado: (2020)

High-Throughput Network Communication with NetIO
por: Schumacher, J\"orn, et al.
Publicado: (2016)

Lessons Learned, Challenges Taken, and Actions Made for “Precision” Immunohistochemistry. Analysis and Perspectives From the NordiQC Proficiency Testing Program
por: Nielsen, Søren, et al.
Publicado: (2023)

GH Replacement in the Elderly: Is It Worth It?
por: Ricci Bitti, Silvia, et al.
Publicado: (2021)

User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study
por: Tauber, Maithé, et al.
Publicado: (2013)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
por: Lundberg, Elena, et al.
Publicado: (2020)

The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations
por: Dumitriu-Stan, Roxana-Ioana, et al.
Publicado: (2023)

User assessment of Norditropin NordiFlex®, a new prefilled growth hormone pen: a Phase IV multicenter prospective study [Corrigendum]
Publicado: (2013)

A Synthetic dl-Nordihydroguaiaretic acid (Nordy), Inhibits Angiogenesis, Invasion and Proliferation of Glioma Stem Cells within a Zebrafish Xenotransplantation Model
por: Yang, Xiaojun, et al.
Publicado: (2014)

High-throughput and low-latency network communication with NetIO
por: Schumacher, Jorn, et al.
Publicado: (2017)

C# 6.0 and the .NET 4.6 framework
por: Troelsen, Andrew W, et al.
Publicado: (2015)

Impact of Growth Hormone (GH) Deficiency and GH Replacement upon Thymus Function in Adult Patients
por: Morrhaye, Gabriel, et al.
Publicado: (2009)

Examining the Suitability of NetFlow Features in Detecting IoT Network Intrusions
por: Awad, Mohammed, et al.
Publicado: (2022)

Regulation of GH and GH Signaling by Nutrients
por: Caputo, Marina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_partg2upjgm73m1u6l6jhllv5h